New research suggests that some of the world's most commonly prescribed painkillers may offer limited benefit over alternatives for several acute pain conditions, while carrying a higher risk of side effects.
Opioids are a family of drugs that includes medicines like morphine, codeine, oxycodone, and tramadol. These are among the most commonly prescribed painkillers in the world. Doctors use them routinely when patients arrive at emergency rooms or clinics with sudden muscle pain, back injuries, sprains, joint problems, or stomach conditions such as acute pancreatitis, a painful swelling of the pancreas.
A growing body of research now asks a hard question: are these powerful drugs actually helping or harming?
Multiple studies suggest that opioids, at least in pill form, may not be as effective at relieving sudden pain as most people assume. And the risks, researchers argue, are not being communicated clearly enough to patients.
What did the studies find?
One such study, a systematic review and meta-analysis published in 2022, looked at a very specific and common problem: the severe abdominal pain that accompanies acute pancreatitis.
There are no clear medical guidelines on how best to manage that pain in hospital, so the review pooled seven smaller trials involving a total of 389 patients and compared how opioids and non-opioids performed.
The findings were striking. On the first day of treatment, patients who received opioids felt no better than those who received non-opioid medicines. Patients on non-opioids were more likely to ask for additional pain relief. However, when the analysis compared opioids only against non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol, even that gap disappeared. These widely available medicines worked just as well as opioids without increasing the need for top-up doses.
"Opioids did not show a significant increase in the complications of pancreatitis, nausea and vomiting, sedation, and deaths when compared with nonopioids," the study stated. But the overall profile of unwanted effects was better in the non-opioid group.
The study concluded that NSAIDs and paracetamol can provide adequate pain relief in patients with acute pancreatitis, with fewer side effects and no meaningful increase in the need for extra medication. It also noted that the results should be interpreted with caution, given the diversity of medications used across the trials, the small sample sizes, and unclear bias in several trials.
A 2024 systematic review and meta-analysis examined whether opioids reduce pain in people with acute musculoskeletal injuries, looking at 17 trials.
For adults, oral opioids did reduce pain more than a placebo in the short term, but the difference was small. On a pain scale of 0 to 100, patients on opioids rated their pain roughly 8.8 points lower than those on placebo — a gap unlikely to represent a meaningful difference in how a patient actually feels or functions day to day.
On disability — whether opioids helped people move and carry out daily activities better — the evidence was too uncertain to draw any conclusion. Opioid users were, however, at a substantially higher risk of side effects than those on placebo.
The review found one setting in which opioids appeared to work markedly better. When morphine was delivered directly into a vein rather than swallowed as a pill, patients with sciatica — a shooting nerve pain that runs down the leg — experienced large and meaningful pain relief. In a single study of 197 patients, the pain reduction was large and clinically significant.
For children, the findings were more discouraging. Across three trials, oral opioids showed no meaningful benefit over placebo for pain, and there was insufficient data to assess their effect on disability in paediatric patients.
The study concluded that doctors should weigh the limited short-term gains of opioid pills against the uncertain safety picture, especially given how commonly these drugs are prescribed for common injuries.
A 2026 overview of systematic reviews examined 59 existing reviews of trials on opioid use for any kind of sudden, non-cancer pain. It found that opioids are effective in certain specific contexts.
For abdominal pain, certain opioids — including morphine, oxycodone, tramadol, and papaveretum — reduced pain quickly and significantly, with high-certainty evidence. For pain following dental surgery and a common ear procedure called myringotomy, opioids showed moderate benefits.
For musculoskeletal pain, mostly associated with injuries, back pain, or sprains, the picture was more limited. Oral opioids provided only a very small reduction in pain over the medium term, and the risk of side effects in this group also increased.
The overview highlighted a consistent gap in the existing research: most studies looked at single doses and tracked outcomes for no longer than 48 hours, meaning there is limited information about how opioids perform when taken over several days — which is often how they are prescribed in practice.
The study concluded that while opioids have a role in managing some types of acute pain, such as post-surgical dental pain, the evidence for their use across all acute pain conditions is uneven and often limited.
Experts urge caution on opioid use
Dr Amit Gupta, senior consultant paediatrician and neonatologist at Motherhood Hospitals, Noida, said that for most musculoskeletal injuries in children, safer alternatives are available. "For most musculoskeletal injuries, safer options such as paracetamol, ibuprofen, and rest can be advised to children," he said.
Dr Gupta noted that milder cases of pancreatitis can be managed without opioids. "When it comes to mild to moderate acute pancreatitis, the pain can be relieved with NSAIDs and paracetamol," he said, adding that opioids remain an option "in case of severe or persistent pain."
He added that non-opioid pain relievers are the first line of treatment for paediatric patients. "Opioids will only be used in case of severe pain," he said, noting that when opioids are prescribed, children are closely monitored for pain and recovery.
This story was produced in collaboration with First Check, the health journalism vertical of DataLEADS.
